Visual Abstract

Visual Abstract
Visual Abstract.
View largeDownload slide
Keywords:
Klotho, Minicircle, Ischemia reperfusion injury, Unilateral ureteral obstruction, Drug delivery

Background: Klotho treatment is a promising approach against kidney injury, but its clinical application is still undetermined. We developed a novel strategy to allow self-production of Klotho protein, using minicircle (MC) technology, and evaluated its feasibility in therapeutic Klotho delivery. Methods: We engineered MC vectors to carry cassette sequences of Klotho and verified the self-production of Klotho protein from in HEK293T cells. We evaluated the location and persistence of delivered MC in vivo, and the duration of Klotho protein production from MCs by serial measurement of Klotho protein in blood. We subsequently evaluated the therapeutic potential of Klotho-encoding MCs in experimental model of renal injury. Results: We confirmed the production of Klotho from MC by its significant availability in cells transfected with the MC, as well as in its conditioned medium, compared to that in cells transfected with parent vector. MCs were delivered in vivo by hydrodynamic injection via tail vein. After a single injection of MCs, red fluorescence protein was detected until 30 days in liver, and Klotho protein was maintained until 10 days in the blood, suggesting the production of Klotho protein from MCs via protein synthesis machinery in liver. Therapeutic effect of MC was confirmed by functional and histological improvement seen in mouse model of acute ischemia-reperfusion injury and unilateral ureteral obstruction. Conclusion: Together, these findings implied that self-generated Klotho protein, using MC technology, is functionally active and relevant as a therapeutic approach in renal injury.

Keywords:
Klotho, Minicircle, Ischemia reperfusion injury, Unilateral ureteral obstruction, Drug delivery
1.
Hu MC, Shi M, Zhang J, Quiñones H, Kuro-o M, Moe OW. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective.
Kidney Int
. 2010 Dec; 78(12): 1240–51.
2.
Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, et al. Klotho deficiency causes vascular calcification in chronic kidney disease.
J Am Soc Nephrol
. 2011 Jan; 22(1): 124–36.
3.
Sugiura H, Yoshida T, Tsuchiya K, Mitobe M, Nishimura S, Shirota S, et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure.
Nephrol Dial Transplant
. 2005 Dec; 20(12): 2636–45.
4.
Seibert E, Radler D, Ulrich C, Hanika S, Fiedler R, Girndt M. Serum klotho levels in acute kidney injury.
Clin Nephrol
. 2017 Apr; 87(4): 173–9.
5.
Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, et al. Severely reduced production of klotho in human chronic renal failure kidney.
Biochem Biophys Res Commun
. 2001 Feb; 280(4): 1015–20.
6.
Hu MC, Shi M, Zhang J, Addo T, Cho HJ, Barker SL, et al. Renal production, uptake, and handling of circulating alphaklotho.
J Am Soc Nephrol
. 2016 Jan; 27(1): 79–90.
7.
Lim SW, Jin L, Luo K, Jin J, Shin YJ, Hong SY, et al. Klotho enhances FoxO3-mediated manganese superoxide dismutase expression by negatively regulating PI3K/AKT pathway during tacrolimus-induced oxidative stress.
Cell Death Dis
. 2017 Aug; 8(8):e2972.
8.
Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH 3rd, et al. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of klotho.
Clin Cancer Res
. 2017 Jun; 23(12): 3181–90.
9.
Chen TH, Kuro-O M, Chen CH, Sue YM, Chen YC, Wu HH, et al. The secreted Klotho protein restores phosphate retention and suppresses accelerated aging in Klotho mutant mice.
Eur J Pharmacol
. 2013 Jan; 698(1-3): 67–73.
10.
Leon J, Moreno AJ, Garay BI, Chalkley RJ, Burlingame AL, Wang D, et al. Peripheral elevation of a klotho fragment enhances brain function and resilience in young, aging, and alpha-synuclein transgenic mice.
Cell Rep
. 2017 Aug; 20(6): 1360–71.
11.
Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo.
Mol Ther
. 2003 Sep; 8(3): 495–500.
12.
Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo.
Hum Gene Ther
. 2005 Jan; 16(1): 126–31.
13.
Gill DR, Pringle IA, Hyde SC. Progress and prospects: the design and production of plasmid vectors.
Gene Ther
. 2009 Feb; 16(2): 165–71.
14.
Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors.
Nat Biotechnol
. 2010 Dec; 28(12): 1287–9.
15.
Herweijer H, Wolff JA. Gene therapy progress and prospects: hydrodynamic gene delivery.
Gene Ther
. 2007 Jan; 14(2): 99–107.
16.
Wei Q, Dong Z. Mouse model of ischemic acute kidney injury: technical notes and tricks.
Am J Physiol Renal Physiol
. 2012 Dec; 303(11):F1487–94.
17.
Maruyama H, Higuchi N, Nishikawa Y, Kameda S, Iino N, Kazama JJ, et al. High-level expression of naked DNA delivered to rat liver via tail vein injection.
J Gene Med
. 2002 May-Jun; 4(3): 333–41.
18.
Wolff JA, Budker V. The mechanism of naked DNA uptake and expression.
Adv Genet
. 2005; 54: 3–20.
19.
Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications.
Mol Ther
. 2007 Dec; 15(12): 2063–9.
20.
Andrianaivo F, Lecocq M, Wattiaux-De Coninck S, Wattiaux R, Jadot M. Hydrodynamics-based transfection of the liver: entrance into hepatocytes of DNA that causes expression takes place very early after injection.
J Gene Med
. 2004 Aug; 6(8): 877–83.
21.
Kobayashi N, Nishikawa M, Hirata K, Takakura Y. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery.
J Gene Med
. 2004 May; 6(5): 584–92.
22.
Zhang X, Collins L, Sawyer GJ, Dong X, Qiu Y, Fabre JW. In vivo gene delivery via portal vein and bile duct to individual lobes of the rat liver using a polylysine-based nonviral DNA vector in combination with chloroquine.
Hum Gene Ther
. 2001 Dec; 12(18): 2179–90.
23.
Hu MC, Shi M, Gillings N, Flores B, Takahashi M, Kuro-O M, et al. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
Kidney Int
. 2017 May; 91(5): 1104–14.
24.
Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.
J Am Soc Nephrol
. 2015 Jun; 26(6): 1290–302.
25.
Ravikumar P, Li L, Ye J, Shi M, Taniguchi M, Zhang J, et al. αKlotho deficiency in acute kidney injury contributes to lung damage.
J Appl Physiol (1985)
. 2016 Apr; 120(7): 723–32.
26.
Sugiura H, Yoshida T, Shiohira S, Kohei J, Mitobe M, Kurosu H, et al. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis.
Am J Physiol Renal Physiol
. 2012 May; 302(10):F1252–64.
27.
Zhou L, Li Y, Zhou D, Tan RJ, Liu Y. Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling.
J Am Soc Nephrol
. 2013 Apr; 24(5): 771–85.
28.
Hu MC, Kuro-o M, Moe OW. Klotho and kidney disease.
J Nephrol
. 2010 Nov-Dec; 23 Suppl 16:S136–44.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.